Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering

Scientific Reports

Volumn 4, Issue , 2015, Pages

  Thakkar, Shraddha ^a   Nanaware Kharade, Nisha ^a   Celikel, Reha ^a   Peterson, Eric C ^a   Varughese, Kottayil I ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; PROTEIN BINDING; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; BINDING SITE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GENETICS; MOLECULAR GENETICS; MUTATION; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMPHETAMINE; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING SITES; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; METHAMPHETAMINE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN ENGINEERING; SINGLE-CHAIN ANTIBODIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84905268179     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03673     Document Type: Article

References (31)

1. Nicosia, N., Pacula, R. L., Kilmer, B. & L. R. a. C. J. The Economic Cost of Methamphetamine Use in the United States, 2005. Drug Policy Research Center. RAND Corporation Monograph Series. www.rand.org/pubs/monographs/2009/RAND-MG829.pdf 2009).
2. Galloway, G. P. et al. An examination of drug craving over time in abstinent methamphetamine users. Am. J. Addict. 19, 510-514 (2010).
3. Hillhouse, M. P., Marinelli-Casey, P., Gonzales, R., Ang, A. & Rawson, R. A. Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. Addiction 102 Suppl 1, 84-95 (2007).
4. Owens, S.M., Atchley, W. T., Hambuchen, M. D., Peterson, E. C. & Gentry, W. B. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (1)- methamphetamine addiction. CNS. Neurol. Disord. Drug Targets. 10, 892-898 (2011).
5. Peterson, E. C. & Owens, S.M. Designing immunotherapies to thwart drug abuse. Mol. Interv. 9, 119-124 (2009).
6. Laurenzana, E. M. et al. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos. 31, 1320-1326 (2003).
7. Byrnes-Blake, K. A., Laurenzana, E. M., Landes, R. D., Gentry, W. B. & Owens, S. M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur. J. Pharmacol. 521, 86-94 (2005).
8. Gentry, W. B. et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int. Immunopharmacol. 6, 968-977 (2006).
9. Byrnes-Blake, K. A. et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur. J. Pharmacol. 461, 119-128 (2003).
10. Milesi-Halle, A., Hendrickson, H. P., Laurenzana, E. M., Gentry, W. B. & Owens, S. M. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol. Appl. Pharmacol. 209, 203-213 (2005).
11. McMillan, D. E. et al. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther. 309, 1248-1255 (2004).
12. Peterson, E. C., Laurenzana, E. M., Atchley, W. T., Hendrickson, H. P. & Owens, S. M. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J. Pharmacol. Exp. Ther. 325, 124-133 (2008).
13. Peterson, E. C. et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther. 322, 30-39 (2007).
14. Celikel, R., Peterson, E. C., Owens, S.M. & Varughese, K. I. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Sci. 18, 2336-2345 (2009).
15. Hanes, J., Schaffitzel, C., Knappik, A. & Pluckthun, A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18, 1287-1292 (2000).
16. Wu, H. et al. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc. Natl. Acad. Sci. U. S. A 95, 6037-6042 (1998).
17. Kurtzman, A. L. et al. Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr. Opin. Biotechnol. 12, 361-370 (2001).
18. Boder, E. T., Midelfort, K. S. & Wittrup, K. D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. U. S. A. 97, 10701-10705 (2000).
19. Jorgensen, W. L. The many roles of computation in drug discovery. Science 303, 1813-1818 (2004).
20. Clark, L. A. et al.Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci 15, 949-960 (2006).
21. Kauzmann, W. Some factors in the interpretation of protein denaturation. Adv. Protein Chem. 14, 1-63 (1959).
22. Quiocho, F. A., Wilson, D. K. & Vyas, N. K. Substrate specificity and affinity of a protein modulated by bound water molecules. Nature 340, 404-407 (1989).
23. Celikel, R., Ruggeri, Z. M. & Varughese, K. I. von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat. Struct. Biol. 7, 881 (2000).
24. Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136 (2005).
25. Nanaware-Kharade, N., Gonzalez, G. A., III, Lay, J. O., Jr., Hendrickson, H. P. & Peterson, E. C. Therapeutic anti-methamphetamine antibody fragmentnanoparticle conjugates: synthesis and in vitro characterization. Bioconjug. Chem. 23, 1864-1872 (2012).
26. Sambrook, J. & Russel, D. W. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 2001).
27. Akera, T. & Cheng, V. K. A simple method for the determination of affinity and binding site concentration in receptor binding studies. Biochim. Biophys. Acta 470, 412-423 (1977).
28. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
29. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126-2132 (2004).
30. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D. Biol. Crystallogr. 53, 240-255 (1997).
31. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol Crystallogr. 67, 235-242 (2011).